822 results about "Contrast medium" patented technology

The application discloses a multi-marked endoscopic imaging lens for digestive tract, and belongs to the field of biomedical microscopic endoscopic imaging. The endoscopic imaging lens comprises a first lens, a second lens, a third lens, a fourth lens, a fifth lens, a sixth lens and a seventh lens; the first lens focuses laser; the second lens is matched with the first lens to limit a light beam in an effective light aperture of the lens; the third lens corrects chromatic aberration; the fourth lens and the fifth lens are combined to correct aberration; the sixth lens adopts an aspheric lens to correct spherical aberration caused in a collimating and focusing system; and the seventh lens is matched with the sixth lens to correct chromatic aberration. The working spectral range of the microscopic objective lens group is 488-860 nm, the effective light aperture is less than 1.8 mm, the mechanical outer diameter is not greater than 2.6 mm, the numerical aperture at the object side or the tissue is 0.55, the imaging field of view is 450 microns, the magnification is 2.14 times, and the working distance is 84 microns. The effect of matching excitation and fluorescence spectrum of a clinically available fluorescence contrast agent is realized.

The invention relates to the technical field of medical data processing, and discloses a non-invasive hemodynamic assessment system for coronary artery stenosis degree, comprising an image acquisition module used for acquiring a coronary artery computed tomography angiography image of a patient; the physiological signal acquisition module is used for synchronously acquiring physiological signals of a patient, and the physiological signals comprise electrocardiosignals and non-invasive arterial blood pressure signals; and the data processing module is used for preprocessing and segmenting the coronary artery computed tomography angiography image. Electrocardiogram and non-invasive arterial blood pressure signals are collected through the sensor, risks and complications caused by invasive examination of traditional coronary artery radiography are avoided, the problem that patients unsuitable for invasive examination such as contrast agent allergy and renal insufficiency are difficult to evaluate is solved, the pain of the patients is relieved, and the acceptability of the patients is improved.

The invention is suitable for the technical field of ultrasonic imaging, and provides a three-dimensional ultrasonic imaging method and system, computer equipment and a computer program product, and the method comprises the steps: transmitting a multi-angle composite plane wave sequence to a target region through a one-dimensional ultrasonic array with the frequency gradual change characteristic in the elevation direction, and receiving a reflected echo signal sequence, generating a target gray-scale image sequence corresponding to the echo signal sequence, acquiring coordinates of each ultrasonic contrast agent microbubble in each frame of gray-scale image, generating a two-dimensional coordinate set, calculating the axial half-peak full width of a point spread function region of each ultrasonic contrast agent microbubble, and calculating the axial half-peak full width of the point spread function region of each ultrasonic contrast agent microbubble; determining the coordinate of each ultrasonic contrast agent microbubble in the elevation angle direction based on the axial half-peak full width, generating an elevation angle coordinate set, and generating a three-dimensional contrast image of the target area based on the two-dimensional coordinate set and the elevation angle coordinate set. According to the method provided by the invention, the problem that three-dimensional ultrasonic imaging is limited by the surface ultrasonic array can be solved, and low-cost, simple and efficient three-dimensional ultrasonic imaging based on the one-dimensional ultrasonic array is realized.

A solution for training a machine learning model (305) for use in medical imaging applications is presented. A corresponding method (400) includes providing (403-410) an incomplete sample set for each imaging process, each incomplete sample set including one (or more) sample target images and one (or more) sample baseline images for a sample target dose of contrast agent. One (411-445; 450-456) sample source images are simulated (411-445; 450-456) from each of the incomplete sample sets (or a portion thereof) to mimic contrast agent at a sample source dose that is lower than the sample target dose. One or more complete sample sets are generated (446; 457) for each imaging process by combining the incomplete sample sets with sample source images that have been simulated from other incomplete sample sets. The machine learning model (305) is then trained (458-473) using the complete set of samples. Further, a method of using a machine learning model in medical imaging applications is presented. A computer program (300) and a computer program product for implementing a method (400) are presented. Furthermore, a computing system (130) for executing the method (400) is presented. A corresponding medical method is also presented.

The invention provides a pulmonary artery embolism imaging method, and relates to the field of magnetic resonance imaging. According to the specific implementation scheme, an acquisition window is determined according to electrocardio data and diaphragm navigation data of an adaptive patient; according to the collection window, original frequency domain data are collected in a Cartesian filling mode; performing phase compensation on the original frequency domain data by utilizing pulmonary artery pulse vector field modeling and a dynamic compensation algorithm to obtain proportionality coefficient spatial data; and performing compressed sensing reconstruction on the proportionality coefficient spatial data to generate a three-dimensional pulmonary artery image. The scheme is used for detecting pulmonary artery embolism in the free breathing state, no contrast agent is needed, radiation is avoided, and the universality of applicable people and the inspection safety are improved. According to the technology, by reducing artifact interference and optimizing image quality and scanning efficiency, rapid and accurate diagnosis is achieved, the comfort level of a patient and clinical diagnosis efficiency are remarkably improved, and the technology has important application value and social benefits.

The invention relates to the related technical field of medical instruments, in particular to a contrast injection device for enhancing nuclear magnetic resonance, which comprises a base, a mounting shell arranged at the upper part of the base, a first barrel arranged at the left upper part in the mounting shell, a second barrel arranged at the right upper part in the mounting shell, and a mixing barrel arranged in the middle of the upper part of the mounting shell, a first piston rod is arranged in the first barrel, a second piston rod is arranged in the second barrel, communicating pipes are respectively communicated between the first barrel and the mixing barrel and between the second barrel and the mixing barrel, a one-way water inlet pipe is arranged at the top of the barrel, and the one-way water inlet pipe is communicated with an external liquid storage tank. By rotating the adjusting screw rod, the adjusting screw rod drives the first wedge-shaped block to move to the position of the needed dosage, then the rodless air cylinder controls the extrusion plate to move upwards, and after the extrusion plate moves upwards and makes contact with the plate body, the piston rods move upwards to inject the contrast agent and normal saline of the corresponding dosage into the mixing barrel to be mixed.

The invention provides a novel macrocyclic compound, a gadolinium chelate thereof, a method for preparing the compound and application of the compound as a magnetic resonance contrast agent. The compound has pertinence on magnetic resonance detection of liver focal lesions and can be used for liver specific imaging.

An aqueous pharmaceutical composition including compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

The invention discloses a blood vessel inner diameter correction method and device based on an X-ray total attenuation conservation principle and a storage medium, and belongs to the technical field of medical image processing. The core of the method is to discover and utilize the total net attenuation of a blood vessel filled with a contrast agent in an actual motion state and the total net attenuation of the blood vessel in an ideal static state to be kept in conservation. The method comprises the steps that an angiography image is acquired, and a target area and an initial inner diameter measuring line are determined; calculating the gray scale decline amount and the maximum value of each pixel of the line; on the basis of the conservation principle, the inner diameter of the blood vessel in an ideal state is inversely calculated through the formula that the inner diameter is corrected to be equal to sigma [(delta Ii / delta Imax) * Li]. Furthermore, based on the same principle, the method can be expanded and applied to correction of the two-dimensional contour of the target blood vessel. According to the method, errors caused by motion artifacts and resolution limitation are fundamentally compensated through a volume measurement method based on integration and distribution, and the method is particularly suitable for accurate measurement of severe stenosis blood vessels.

The invention relates to the technical field of blood vessel stenosis grading, in particular to a blood vessel stenosis degree grading system based on coronary angiography images. The method comprises the following steps: dividing a vascular skeleton line of an angiography image into vascular segments based on a bifurcation point, and determining a stenosis point on the vascular segment according to the blood flow velocity difference of the vascular segment at the front edge position of a contrast agent in each frame of angiography image and a neighborhood angiography image; according to the blood vessel diameter difference between each bifurcation point and the other bifurcation points and the distance between the other bifurcation points and the main blood vessel section, a reference adaptation degree is obtained, a reference point of each bifurcation point is selected, and according to the blood flow speed difference between each bifurcation point and the branch blood vessel section of the reference point and the reference adaptation degree, narrow points in the bifurcation points are screened; and grading the blood vessel stenosis degree based on the blood vessel diameter of the stenosis point. The blood vessel skeleton line is divided into two conditions of the blood vessel segment and the bifurcation point to analyze the blood vessel physiological stenosis position, and the accuracy of positioning the pathological stenosis position in the coronary artery is improved.

A contrast agent for imaging lymph nodes or lymphatic vessels with near-infrared light that can selectively image primary lymph nodes relative to secondary or higher lymph nodes. A dose of the composition suitable for imaging lymph nodes or lymphatic vessels.

The gadolinium-based cationic polymer contrast agent is synthesized by chelating a cationic polymer and gadolinium ions, has high biological safety and can be used for cartilage imaging. The prepared contrast agent adopts an articular cavity direct injection method, so that the imaging effect is improved, and the contrast dosage is reduced. When the cartilage activity is normal, the content of glycosaminoglycan in the matrix is rich, and when the cartilage is inactivated or the activity is reduced, the content of glycosaminoglycan in the matrix is obviously reduced. The gadolinium-based cationic polymer contrast agent is combined with negatively charged glycosaminoglycan in a cartilage matrix through the charge effect. The gadolinium-based cationic polymer contrast agent can be used for noninvasive and quantitative evaluation of cartilage activity in nuclear magnetic resonance imaging, especially cartilage activity and stability in transplantation.

An ultrasound diagnosis apparatus includes: a transmission and reception circuitry configured to perform, via an ultrasound probe, a first ultrasound scan on a first region in a subject who has a contrast agent injected and a second ultrasound scan on at least a part of a second region in the subject overlapping with the first region, the second ultrasound scan including transmitting and receiving two types of ultrasound waves of which one or both of amplitude levels and phases are different from each other; and processing circuitry configured to generate a blood flow image corresponding to one frame by implementing a Doppler method on the basis of a data sequence including reception data obtained from the first ultrasound scan performed multiple times in mutually the same position within the first region to have the second ultrasound scan performed in-between and to generate a contrast-enhanced image based on a result of the second ultrasound scan performed at least one time.

The present invention relates to an artificial intelligence-based device and method for determining amyloid PET positivity, wherein a normal-appearing white matter dominance ratio is used and amyloid PET positivity is automatically determined based on machine learning, thereby improving the accuracy and sensitivity of amyloid PET positivity determination. The device comprises: an image acquisition unit for acquiring PET and MRI images of the brain of a diagnostic subject administered with a contrast agent, the images being acquired through tomographic scanning; a segmentation unit for segmenting normal-appearing white matter (NAWM) and white matter hyperintensity (WMH) from a fluid attenuated inversion recovery (FLAIR) image obtained from the MRI image; a standardized uptake value ratio (SUVR) calculation unit for calculating a global standardized uptake value ratio (SUVR) and a standardized uptake value ratio in normal-appearing white matter (NAWM SUVR), on the basis of the PET image and the NAWM region segmented by the segmentation unit; and an amyloid PET positivity determination unit for determining amyloid PET positivity by inputting the global SUVR and the NAWM dominance ratio (NDR) into a pre-trained prediction model, wherein the NDR is a value obtained by dividing the global SUVR by the NAWM SUVR.

An ultrasound transducer ultrasonically processes a target volume by emitting a sequence of acoustic pulses to the target volume to alter tissue properties while at least one acoustic detector detects an ultrasound reflected signal from the target volume after each acoustic pulse, and a controller (i) estimates an activity of the contrast agent at the target volume based on a comparison between values of signal parameters in the reflected signal following successive acoustic pulses, and (ii) controls the ultrasound transducer to alter the tissue property based on the estimated activity.

The invention discloses a human brain specific fluid flow direction identification method comprising the following steps: S1, multi-input network model construction: using a decoder to segment a task, and introducing a boundary detection task; high-density lesions and surrounding edema in the medical image are accurately segmented according to the Vi < T > and an attention mechanism; s2, fluid mechanics model construction and parameter setting, focus classification and risk quantification: optimizing time windows of two times of CT scanning; constructing a three-dimensional geometric model of high-density lesions, peripheral edema and normal brain tissue RO I; constructing initial physical field distribution; setting boundary conditions corresponding to a vascular rupture source and a focus drainage area; and dynamically adjusting the time step length based on the flow velocity and the diffusion coefficient. The invention provides a human brain specific fluid flow direction identification method, which combines image high-dimensional features with a multi-physics field coupling model, and reveals the heterogeneity of human brain specific fluid-blood conversion and contrast agent leakage in absorption and peripheral edema expansion modes.

A method may be performed by a system including a processor in communication with an extraluminal imaging device and an intravascular pressure measurement device. The method includes acquiring a contrast agent angiography image in a blood vessel having a contrast agent; based on the contrast agent angiography image, generating a reconstructed geometric object of the blood vessel and estimating blood flow in the blood vessel; implementing a physical model of blood distribution using the reconstructed geometry, determining output parameters based on the blood pressure value and the blood flow volume; and generating a harmonic hemodynamic parameter based on the output parameter. The harmonized hemodynamic parameter is adjusted based on measurements taken at various vascular conditions.

The invention discloses a cerebral artery blood flow velocity prediction method, device and equipment and a medium, and relates to the field of blood flow velocity prediction.The method comprises the steps that cerebral artery nuclear magnetic imaging data are obtained and preprocessed; performing image segmentation to obtain a cerebral artery three-dimensional model; extracting geometric topology information of the cerebral artery; constructing a 0-1-dimensional geometric multi-scale model of the crowd averaged cerebral artery; determining entrance boundary conditions of the 0-1-dimensional model to obtain a 0-1-dimensional patient personalized hemodynamic model; according to a clinical preset contrast agent concentration-time curve and based on the law of conservation of mass, a 0-1-dimensional patient personalized hemodynamic model is used for simulating a contrast agent injection process, and a contrast agent concentration-time curve of each position in the cerebral artery topology network is obtained; based on the concentration data of the contrast agent at the near end and the far end of the target blood vessel, the flow velocity of the contrast agent at different blood vessel segments of the cerebral artery is determined, and the method can be suitable for blood flow velocity estimation of an artery system with a complex topological structure.

The invention discloses a multi-mode whole-body blood vessel magnetic resonance imaging method and device, and the method comprises the steps: displaying prompt information for carrying out the cascade wrapping of a whole-body magnetic resonance coil and the input of a contrast agent for a target object, and enabling the contrast agent to be polysaccharide superparamagnetic iron oxide; setting a signal mark point on the constructed whole body positioning image and configuring a multi-modal imaging sequence; emitting a magnetic resonance radio frequency pulse, and receiving a coil electric signal transmitted by the whole body magnetic resonance coil; determining the signal intensity of each set signal mark point according to the coil electric signal; when the signal intensity is larger than a preset threshold value, whole-body blood vessel scanning is conducted on the target object through the multi-mode imaging sequence; and performing image reconstruction according to the scanned target image sequence to generate a whole body blood vessel image. By adopting the embodiment of the invention, one-stop imaging of large and small blood vessels of the whole body can be realized at one time by utilizing a scanning mode of cascading wrapping of the whole body magnetic resonance coil, so that the scanning time is greatly shortened, and the blood vessel imaging efficiency is improved.

The application discloses an ultrasonic-temperature double-triggered double-liquid gas phase change contrast agent and a preparation method thereof. The preparation steps comprise the following steps: adding an isotonic buffer solution into a prepared composite phospholipid film, oscillating after ultrasonic dispersion, obtaining a targeted phospholipid vesicle dispersion; then high-pressure double-liquid co-loading is carried out, and the phase change temperature and the ultrasonic response are calibrated; filtering through a filter membrane, collecting the precipitate after centrifugation, adding a protective solution after washing with a PBS buffer solution, and sealing and storing to obtain the double-liquid gas phase change contrast agent. After the contrast agent enters the body, under the ultrasonic double triggering of the physiological temperature and an ultrasonic imaging instrument, the double-liquid gas synchronously phase changes into a gaseous state, drives the contrast agent to rapidly expand from a nano-sized particle into a micron-sized microbubble, realizes ultrasonic enhanced imaging, and has a significant clinical application value.

The invention provides an esophageal stenosis dilatation balloon which comprises a dilatation tube mechanism, and a guide-in assembly and a suction tube are arranged in the dilatation tube mechanism; the balloon main body is arranged on the outer surface wall of the expansion tube mechanism, the balloon main body is communicated with the guide-in assembly, a contrast agent can be injected through the injection device to expand the balloon main body, the expansion diameter is matched with the injection pressure, repeated suction can be carried out to gradually expand the balloon main body to a target diameter, and marking lines visible under X rays are arranged at the two ends of the balloon main body. The invention relates to the technical field of medical instruments, in particular to a balloon which is convenient for real-time observation of dilatation during operation and capable of accurately controlling the dilatation diameter of a balloon main body by injecting a contrast agent and utilizing the matching relation between the contrast agent and pressure, avoiding blind operation and improving safety. Suction and injection can be repeatedly carried out, and progressive and controllable expansion is achieved.

The invention belongs to the technical field of medical instruments. In order to solve the problem that an existing device is tedious in operation, the multifunctional automatic injection system is designed and comprises an injector, an automatic injection device and an auxiliary Y valve, and the auxiliary Y valve is connected with a catheter, a guide wire and the automatic injection device. Therefore, the automatic injection device can inject the contrast agent, the medicine or the embolic agent in the injector, the contrast or treatment efficiency is improved, meanwhile, the guide wire can be rapidly fixed, the guide wire does not need to be completely withdrawn out of the catheter, the surgical operation difficulty is reduced, and the surgical time is shortened.

The present application relates to an aneurysm treatment device for implanting into an aneurysm, comprising: a balloon including a hollow balloon body, the balloon body being inflatable or contractible, the balloon body having an opening, the balloon body being capable of entering into the aneurysm, the balloon body being capable of allowing filling or discharging of contrast agent; and an inflation assembly arranged in the balloon body, the inflation assembly being used for supporting the balloon body and opening or closing the opening, the inflation assembly being capable of sealing the balloon body when the inflation assembly closes the opening; when the balloon body is filled with the contrast agent, the balloon body is inflated and an outer wall thereof is capable of abutting against at least part of an inner wall of the aneurysm; when the balloon body discharges the contrast agent, the balloon body is contracted and a negative pressure effect is capable of reducing the aneurysm. Thus, the size of the aneurysm can be reduced after the operation, and the aneurysm space occupation can be avoided.

The invention discloses an acute kidney injury nuclear magnetic resonance detection contrast agent as well as a preparation method and application thereof. The lipidosome comprises a first lipid component and a second lipid component, the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine, and the second lipid component is a sterol derivative, and the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine. The molar ratio of the first lipid component to the second lipid component is (1-3): 1. According to the invention, all organic free radicals are used for replacing gadolinium ions, so that renal toxicity and systemic fibrosis risks caused by metal accumulation are eliminated, and the method is especially suitable for imaging of patients with renal insufficiency. The material synthesis process is simple, and the cost is controllable. In addition, the system is seamlessly compatible with clinical 3.0 T MRI equipment, additional hardware transformation is not needed, and popularization and application of AKI bedside rapid imaging diagnosis can be directly promoted.

The invention relates to a three-dimensional image construction method and device based on perfusion scanning, computer equipment and a computer readable storage medium. The method comprises the following steps: acquiring scanning data after a scanning object is subjected to multi-circle scanning in a contrast agent perfusion process; according to the scanning data after the multi-circle scanning, obtaining reconstruction data of a plurality of target moments through interpolation operation and reconstruction processing; according to the reconstruction data of the multiple target moments and the mask data of the scanning object, perfusion peak data of the scanning object is obtained; and constructing a three-dimensional image of the scanned object according to the perfusion peak data. By adopting the method, the image quality of the three-dimensional image can be improved.

The invention relates to the technical field of radiotherapy auxiliary instruments, in particular to an injectable calcium sodium alginate hydrogel spacer for radiotherapy and a preparation method of the injectable calcium sodium alginate hydrogel spacer. Nano calcium carbonate is used as an adjusting switch, an adjustable mechanical and degradation performance foundation of the hydrogel is laid, and the material is endowed with unique bifunctional characteristics through the synergistic effect of the nano calcium carbonate, a contrast agent iodized oil and a degradation liquid diethylenetriamine pentaacetic acid. The hydrogel can quickly form gel after being injected, keeps long-term structural stability and clear CT imaging capability in vivo, and can monitor the position and form of the hydrogel in a lossless manner; and when the radiotherapy period is finished, the on-demand and rapid degradation of the hydrogel can be realized only by injecting the diethylenetriamine pentaacetic acid, so that the risk of long-term retention is avoided. In-vitro and in-vivo experiments prove that the material has good biocompatibility, can significantly reduce the radiation dose of normal tissues such as rectum and the like, realizes the technical span from invisibility and difficult degradation to visibility and degradability, and has great clinical transformation value.

Disclosed are methods for quantification of a perivascular space in a subject's central nervous system. The methods include administering contrast agent into cerebrospinal fluid of the subject; performing quantitative ultra-short time-to-echo contrast-enhanced magnetic resonance imaging (QUTE-CE MRI) on a region of interest of the subject's brain; and determining presence of the contrast agent in the perivascular space within the region of interest.

The invention relates to the technical field of image enhancement, in particular to an angiocardiography high-precision angiography enhancement method and system. The method comprises the steps that an ECG curve of electrocardiosignals before and after contrast agent injection of a patient and a blood vessel image are obtained; determining the compressible degree of each wave band according to the change of different wave bands and the change of the heart rate in the QT interval before and after the contrast agent is injected; determining the increment duration of each wave band in combination with the standard duration, the actual duration and the compressible degree; performing standardized adjustment on the ECG time phase of each frame of blood vessel image in combination with the increment time length and the actual time length of each wave band to obtain a standard time phase; determining a mask matched with each negative film according to the standard time phases of the negative films and the masks; and carrying out image subtraction on each negative film and the matched mask, and carrying out angiography enhancement processing. The blood vessel imaging precision after digital subtraction can be improved, the blood vessel artifact phenomenon is reduced, and the blood vessel imaging precision and reliability are enhanced.

The invention relates to a non-gadolinium magnetic resonance contrast agent and a preparation method thereof, and belongs to the field of contrast agents. The invention aims to provide a non-gadolinium contrast agent with high biological safety aiming at the risks of renal fibrosis and cerebral deposition existing in a gadolinium-based magnetic resonance contrast agent. The invention provides a phosphate group modified non-gadolinium magnetic resonance contrast agent. The phosphate group modified non-gadolinium magnetic resonance contrast agent consists of a ligand of a phosphate group substituted trans-cyclohexanediamine tetraacetic acid derivative (tmPCDTA or tqPCDTA) and metal ions Fe < 3 + > or Mn < 2 + >, the contrast agent disclosed by the invention is high in biological safety: endogenous Fe < 3 + > / Mn < 2 + > is used for replacing gadolinium, and cell experiments prove that the survival rate of 4T1 cells is not influenced at the concentration of 500 mu M; clinical applicability is high, kidney excretion is rapid, bladder signals are enhanced 3-5 minutes after mouse intravenous injection, and liver retention is avoided.

An electrical connection material having a contrast agent infused within, and related systems and methods of detection thereof, are disclosed herein. Computer electronics such as printed circuit boards have electronic components attached to a substrate by an electrical connection material. The electrical connection material has at least one component infused with a contrast agent. The contrast agent is of a concentration to provide a visual distinction or highlight when imaged by an inspection system, such as an x-ray system of computed tomography (CT) scanning system. The presence of the contrast agent demonstrates that not all of residual electrical connection material has been cleaned away from the printed circuit board after manufacture.